3 ms·
No i don't think it's hypocritical. Right to try laws allow companies to monetise desperate terminally ill patients. That's been shown repeatedly throughout hi
by olliej 8y ago
No i don't think it's hypocritical.
Right to try laws allow companies to monetise desperate terminally ill patients. That's been shown repeatedly throughout history (and these days in the 'supplements' industry) to result in abuse of dying patients. And you get things like https://www.statnews.com/2017/11/21/herpes-vaccine-hotel-rooms/ https://www.statnews.com/2017/11/21/herpes-vaccine-hotel-roo... which was clearly a great plan - and yeah that's not "terminal", but the exact same kind of thing can happen for terminal diseases as well.
The trial methodology removes the financial incentive, so that now you can't just take all of a dying persons money.
By keeping the treatment in the trial model you also mean that we get data that can actually help -- maybe find out that the drug does not in fact work, or maybe finding out that it does! A patient who is not being treated under trial conditions is much less useful as a data point (if at all) because the placebo effect, and a bunch of other related ones, have repeatedly been found to lead to incorrect feedback - the person says that the drug makes them more comfortable, even though they didn't live any longer, is that because it actually made them feel better? Or was it placebo? Or was it a desire to be "helpful"? If you use them as a data point you may end up with a drug that doesn't actually help, and that drug gets sold. for money. to people who it doesn't help. Cool.